Diagnosis of iron-deficient states

Critical Reviews in Clinical Laboratory Sciences

Volumn 52, Issue 5, 2015, Pages 256-272

  Archer, Natasha M ^a   Brugnara, Carlo ^b  

^a Hematology Division   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Anemia; ferritin; hepcidin; iron; iron deficiency; MCV; reticulocyte; transferrin

Indexed keywords

ERYTHROFERRONE; FERRITIN; GROWTH DIFFERENTIATION FACTOR 15; HEMOGLOBIN; HEPCIDIN; IRON; PROTOPORPHYRIN ZINC; SOLUBLE TRANSFERRIN RECEPTOR; TRANSFERRIN; TRANSFERRIN RECEPTOR; TRANSFERRIN RECEPTOR 2; TRANSMEMBRANE SERINE PROTEASE 6; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ANEMIA; BLOOD CELL COUNT; BLOOD DONOR; ERYTHROCYTE; FERRITIN BLOOD LEVEL; GENETIC POLYMORPHISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON DEPLETION; IRON METABOLISM; IRON THERAPY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DIAGNOSIS; PRIORITY JOURNAL; PROVOCATION TEST; RETICULOCYTE COUNT; RETICULOCYTE HEMOGLOBIN CONTENT; REVIEW; SUBSTITUTION THERAPY; TRANSFERRIN BLOOD LEVEL; ANEMIA, HYPOCHROMIC; ANEMIA, IRON-DEFICIENCY; BLOOD; DIFFERENTIAL DIAGNOSIS; EVIDENCE BASED MEDICINE; GENETIC PREDISPOSITION; GENETICS; METABOLISM;

ANEMIA, HYPOCHROMIC; ANEMIA, IRON-DEFICIENCY; BIOMARKERS; DIAGNOSIS, DIFFERENTIAL; EVIDENCE-BASED MEDICINE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, GENETIC;

EID: 84941744273     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.3109/10408363.2015.1038744     Document Type: Review

References (208)

1. Hallberg L, Hulten L, Gramatkovski E. Iron absorption from the whole diet in men: how effective is the regulation of iron absorption. Am J Clin Nutr 1997;66:347-56.
2. Skikne BS, Cook JD. Effect of enhanced erythropoiesis on iron absorption. J Lab Clin Med 1992;120:746-51.
3. Donovan A, Brownlie A, Zhou Y, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000;403:776-81.
4. Anderson CP, Shen M, Eisenstein RS, et al. Mammalian iron metabolism and its control by iron regulatory proteins. Biochim Biophys Acta 2012;1823:1468-83.
5. Kautz L, Nemeth E. Molecular liaisons between erythropoiesis and iron metabolism. Blood 2014;124:479-82.
6. Schultz IJ, Chen C, Paw BH, et al. Iron and porphyrin trafficking in heme biogenesis. J Biol Chem 2010;285:26753-9.
7. Rouault TA. Biogenesis of iron-sulfur clusters in mammalian cells: new insights and relevance to human disease. Dis Model Mech 2012;5:155-64.
8. Rouault TA. Mammalian iron-sulfur proteins: novel insights into biogenesis and function. Nat Rev Mol Cell Biol 2015;16:45-55.
9. Rajagopal A, Rao AU, Amigo J, et al. Haem homeostasis is regulated by the conserved and concerted functions of HRG-1 proteins. Nature 2008;453:1127-31.
10. White C, Yuan XJ, Schmidt PJ, et al. HRG1 is essential for heme transport from the phagolysosome of macrophages during erythrophagocytosis. Cell Metab 2013;17:261-70.
11. Cook JD, Flowers CH, Skikne BS. The quantitative assessment of body iron. Blood 2003;101:3359-63.
12. Cook JD, Boy E, Flowers C, et al. The influence of high-altitude living on body iron. Blood 2005;106:1441-6.
13. Ganz T, Olbina G, Girelli D, et al. Immunoassay for human serum hepcidin. Blood 2008;112:4292-7.
14. Brugnara C. A hematologic "gold standard" for iron-deficient states? Clin Chem 2002;48:981-2.
15. Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem 2003;49:1573-8.
16. Allen RP, Auerbach S, Bahrain H, et al. The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. Am J Hematol 2013;88:261-4.
17. Auerbach M. The role of intravenous iron for the treatment of restless legs syndrome. Am J Hematol 2014;89:1016. doi: 10.1002/ajh.23820.
18. Spencer BR, Kleinman S, Wright DJ, et al. Restless legs syndrome, pica, and iron status in blood donors. Transfusion 2013;53: 1645-52.
19. Vadasz D, Ries V, Oertel WH. Intravenous iron sucrose for restless legs syndrome in pregnant women with low serum ferritin. Sleep Med 2013;14:1214-16.
20. Lozoff B, Jimenez E, Hagen J, et al. Poorer behavioral and developmental outcome more than 10 years after treatment for iron deficiency in infancy. Pediatrics 2000;105:E51.
21. Congdon EL, Westerlund A, Algarin CR, et al. Iron deficiency in infancy is associated with altered neural correlates of recognition memory at 10 years. J Pediatr 2012;160:1027-33.
22. Lozoff B, Clark KM, Jing Y, et al. Dose-response relationships between iron deficiency with or without anemia and infant social-emotional behavior. J Pediatr 2008;152: 696-702.e3.
23. Lozoff B, Castillo M, Clark KM, et al. Iron supplementation in infancy contributes to more adaptive behavior at 10 years of age. J Nutr 2014;144:838-45.
24. Mei ZG, Cogswell ME, Looker AC, et al. Assessment of iron status in US pregnant women from the National Health and Nutrition Examination Survey (NHANES), 1999-2006. Am J Clin Nutr 2011;93:1312-20.
25. Looker AC, Dallman PR, Carroll MD, et al. Prevalence of iron deficiency in the United States. JAMA 1997;277:973-6.
26. Brotanek JM, Gosz J, Weitzman M, et al. Secular trends in the prevalence of iron deficiency among US toddlers, 1976-2002. Arch Pediatr Adolesc Med 2008;162:374-81.
27. Mei Z, Pfeiffer CM, Looker AC, et al. Serum soluble transferrin receptor concentrations in US preschool children and nonpregnant women of childbearing age from the National Health and Nutrition Examination Survey 2003-2010. Clin Chim Acta 2012;413:1479-84.
28. Frith-Terhune AL, Cogswell ME, Khan LK, et al. Iron deficiency anemia: higher prevalence in Mexican American than in non-Hispanic white females in the third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr 2000; 72:963-8.
29. Pfeiffer CM, Sternberg MR, Caldwell KL, et al. Race-ethnicity is related to biomarkers of iron and iodine status after adjusting for sociodemographic and lifestyle variables in NHANES 2003-2006. J Nutr 2013;143:977S-85S.
30. Kant AK, Graubard BI. Ethnicity is an independent correlate of biomarkers of micronutrient intake and status in American adults. J Nutr 2007;137:2456-63.
31. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010;116: 4754-61.
32. Finch CA. Erythropoiesis, erythropoietin, and iron. Blood 1982; 60:1241-6.
33. Lin DM, Lin ES, Tran MH. Efficacy and safety of erythropoietin and intravenous iron in perioperative blood management: a systematic review. Transf Med Rev 2013;27:221-34.
34. Lippi G, Luca Salvagno G, Montagnana M, et al. Influence of hemolysis on routine clinical chemistry testing. Clin Chem Lab Med 2006;44:311-16.
35. Benyamin B, Ferreira MAR, Willemsen G, et al. Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nat Genet 2009;41:1173-5.
36. Nai A, Pagani A, Silvestri L, et al. TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in normal individuals. Blood 2011;118:4459-62.
37. Galesloot TE, Geurts-Moespot AJ, den Heijer M, et al. Associations of common variants in HFE and TMPRSS6 with iron parameters are independent of serum hepcidin in a general population: a replication study. J Med Genet 2013;50:593-8.
38. Tanaka T, Roy CN, Yao W, et al. A genome-wide association analysis of serum iron concentrations. Blood 2010;115:94-6.
39. Pichler I, Minelli C, Sanna S, et al. Identification of a common variant in the TFR2 gene implicated in the physiological regulation of serum iron levels. Hum Mol Gen 2011;20:1232-40.
40. Hentze MW, Muckenthaler MU, Galy B, et al. Two to tango: regulation of mammalian iron metabolism. Cell 2010;142:24-38.
41. Nai A, Lidonnici MR, Rausa M, et al. The second transferrin receptor regulates red blood cell production in mice. Blood 2014; 125:1170-9.
42. Kasvosve I, Delanghe JR, Gomo ZAR, et al. Transferrin polymorphism influences iron status in blacks. Clin Chem 2000; 46:1535-9.
43. Whitfield JB, Cullen LM, Jazwinska EC, et al. Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am J Hum Gen 2000;66:1246-58.
44. Forni GL, Pinto V, Musso M, et al. Transferrin-immune complex disease: a potentially overlooked gammopathy mediated by IgM and IgG. Am J Hematol 2013;88:1045-9.
45. Bainton DF, Finch CA. The diagnosis of iron deficiency anemia. Am J Med 1964;37:62-70.
46. Kalantar-Zadeh K, McAllister CJ, Lehn RS, et al. A low serum iron level is a predictor of poor outcome in hemodialysis patients. Am J Kidney Dis 2004;43:671-84.
47. Kovesdy CP, Estrada W, Ahmadzadeh S, et al. Association of markers of iron stores with outcomes in patients with nondialysisdependent chronic kidney disease. Clin J Am Soc Nephrol 2009;4: 435-41.
48. Fishbane S, Pollack S, Feldman HI, et al. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol 2009;4:57-61.
49. Cozzi A, Santambrogio P, Privitera D, et al. Human L-ferritin deficiency is characterized by idiopathic generalized seizures and atypical restless leg syndrome. J Exp Med 2013;210:1779-91.
50. Girelli D, Corrocher R, Bisceglia L, et al. Molecular basis for the recently described hereditary hyperferritinemia-cataract syndrome: a mutation in the iron-responsive element of ferritin L-subunit gene (the "Verona mutation"). Blood 1995;86:4050-3.
51. Harris EL, McLaren CE, Reboussin DM, et al. Serum ferritin and transferrin saturation in Asians and Pacific Islanders. Arch Int Med 2007;167:722-6.
52. Mast AE, Blinder MA, Gronowski AM, et al. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem 1998;44:45-51.
53. Leggett BA, Brown NN, Bryant SJ, et al. Factors affecting the concentrations of ferritin in serum in a healthy Australian population. Clin Chem 1990;36:1350-5.
54. Kannengiesser C, Jouanolle AM, Hetet G, et al. New missense mutation in the L ferritin coding sequence associated with elevated levels of glycosylated ferritin in serum and absence of iron overload. Haematologica 2009;94:335-9.
55. Schram AM, Campigotto F, Mullally A, et al. Marked hyperferritinemia does not predict for HLH in the adult population. Blood 2015;125:1548-52.
56. Brugnara C, Zurakowski D, DiCanzio J, et al. Reticulocyte hemoglobin content to diagnose iron deficiency in children. JAMA 1999;281:2225-30.
57. Ullrich C, Wu A, Armsby C, et al. Screening healthy infants for iron deficiency using reticulocyte hemoglobin content. JAMA 2005;294:924-30.
58. KDOQI. Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50: 471-530.
59. Locatelli F, Aljama PA, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19:1-47.
60. Fishbane S, Kowalski EA, Imbriano LJ, et al. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 1996;7: 2654-7.
61. Skikne BS. Serum transferrin receptor. Am J Hematol 2008;83: 872-4.
62. Skikne BS, Flowers CH, Cook JD. Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Blood 1990;75: 1870-6.
63. Khumalo H, Gomo ZAR, Moyo VM, et al. Serum transferrin receptors are decreased in the presence of iron overload. Clin Chem 1998;44:40-4.
64. Ferguson BJ, Skikne BS, Simpson KM, et al. Serum transferrin receptor distinguishes the anemia of chronic disease from iron deficiency anemia. J Lab Clin Med 1992;19:385-90.
65. Punnonen K, Irjala K, Rajamaki A. Iron-deficiency anemia is associated with high concentrations of transferrin receptor in serum. Clin Chem 1994;40:774-6.
66. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997;89:1052-7.
67. Choi JW, Im MW, Pai SH. Serum transferrin receptor concentrations during normal pregnancy. Clin Chem 2000;46:725-7.
68. Fertrin KY, Lanaro C, Franco-Penteado CF, et al. Erythropoiesisdriven regulation of hepcidin in human red cell disorders is better reflected through concentrations of soluble transferrin receptor rather than growth differentiation factor 15. Am J Hematol 2014; 89:385-90.
69. Skikne BS, Punnonen K, Caldron PH, et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol 2011;86: 923-7.
70. Vikstedt R, von Lode P, Takala T, et al. Rapid one-step immunofluorometric assay for measuring soluble transferrin receptor in whole blood. Clin Chem 2004;50:1831-3.
71. Ahluwalia N, Skikne BS, Savin V, et al. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure. Am J Kidney Dis 1997;30:532-41.
72. Singh AK, Coyne DW, Shapiro W, et al. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 2007;71: 1163-71.
73. Fusaro M, Munaretto G, Spinello M, et al. Soluble transferrin receptors and reticulocyte hemoglobin concentration in the assessment of iron deficiency in hemodialysis patients. J Nephrol 2005;18:72-9.
74. Tarng DC, Hung SC, Huang TP. Effect of intravenous ascorbic acid medication on serum levels of soluble transferrin receptor in hemodialysis patients. J Am Soc Nephrol 2004;15:2486-93.
75. Cogswell ME, Looker AC, Pfeiffer CM, et al. Assessment of iron deficiency in US preschool children and nonpregnant females of childbearing age: National Health and Nutrition Examination Survey 2003-2006. Am J Clin Nutr 2009;89:1334-42.
76. Yang Z, Dewey KG, Lönnerdal B, et al. Comparison of plasma ferritin concentration with the ratio of plasma transferrin receptor to ferritin in estimating body iron stores: results of 4 intervention trials. Am J Clin Nutr 2008;87:1892-8.
77. Lee EJ, Oh EJ, Park YJ, et al. Soluble transferrin receptor (sTfR), ferritin, and sTfR/log ferritin index in anemic patients with nonhematologic malignancy and chronic inflammation. Clin Chem 2002;48:1118-21.
78. Chen YC, Hung SC, Tarng DC. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients. Am J Kidney Dis 2006;47: 1036-44.
79. Margetic S, Topic E, Tesija-Kuna A, et al. Soluble serum transferrin receptor and transferrin receptor-ferritin index in anemia of chronic kidney disease. Dial Transplant 2006;35:520-6.
80. Suominen P, Punnonen K, Rajamaki A, et al. Serum transferrin receptor and transferrin receptor-ferritin index identify healthy subjects with subclinical iron deficits. Blood 1998;92:2934-9.
81. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002;48:1066-76.
82. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011; 117:4425-33.
83. Goyal J, McCleskey B, Adamski J. Peering into the future: hepcidin testing. Am J Hematol 2013;88:976-8.
84. Kroot JJC, van Herwaarden AE, Tjalsma H, et al. Second round robin for plasma hepcidin methods: first steps toward harmonization. Am J Hematol 2012;87:977-83.
85. Dallalio G, Fleury T, Means RT. Serum hepcidin in clinical specimens. Br J Haematol 2003;122:996-1000.
86. Mast AE, Foster TM, Pinder HL, et al. Behavioral, biochemical, and genetic analysis of iron metabolism in high-intensity blood donors. Transfusion 2008;48:2197-204.
87. Butterfield AM, Luan P, Witcher DR, et al. A dual-monoclonal sandwich ELISA specific for hepcidin-25. Clin Chem 2010;56: 1725-32.
88. Pardanani A, Finke C, Abdelrahman RA, et al. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. Am J Hematol 2013;88:312-16.
89. Prentice AM, Doherty CP, Abrams SA, et al. Hepcidin is the major predictor of erythrocyte iron incorporation in anemic African children. Blood 2012;119:1922-8.
90. Ukarma L, Johannes H, Beyer U, et al. Hepcidin as a predictor of response to epoetin therapy in anemic cancer patients. Clin Chem 2009;55:1354-60.
91. Steensma DP, Sasu BJ, Sloan JA, et al. The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial. J Clin Oncol 2011;29:2011 (suppl; abstr 9031).
92. Bregman DB, Morris D, Koch TA, et al. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol 2013;88:97-101.
93. Pasricha SR, Atkinson SH, Armitage AE, et al. Expression of the iron hormone hepcidin distinguishes different types of anemia in african children. Sci Transl Med 2014;6:235re3.
94. Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 2014;46: 678-84.
95. Kautz L, Jung G, Nemeth E, Ganz T. The erythroid factor erythroferrone and its role in iron homeostasis. Blood 2013;122:4. www.bloodjournal.org/content/122/21/4.
96. Kautz L, Jung G, Nemeth E, et al. Erythroferrone contributes to recovery from anemia of inflammation. Blood 2014;124:2569-74.
97. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007;13:1096-101.
98. Tamary H, Shalev H, Perez-Avraham G, et al. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood 2008;112:5241-4.
99. Du X, She E, Gelbart T, et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science 2008;320:1088-92.
100. Finberg KE, Heeney MM, Campagna DR, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008;40:569-71.
101. World Health Organization. Worldwide prevalence of anaemia 1993-2005. WHO Global Database on Anaemia. Geneva: WHO; 2008.
102. England JM, Ward SM, Down MC. Microcytosis, anisocytosis and the red cell indices in iron deficiency. Br J Haematol 1976;34: 589-97.
103. Bessman JD, Gilmer Jr PR, Gardner FH. Improved classification of anemias by MCV and RDW. Am J Clin Pathol 1983;80:322-6.
104. Simel DL. Is the RDW-MCV classification of anemia useful? Clin Lab Haematol 1987;9:349-59.
105. Flynn MM, Reppun TS, Bhagavan NV. Limitations of red-bloodcell distribution width (RDW) in evaluation of microcytosis. Am J Clin Pathol 1986;85:445-9.
106. Lafferty JD, Crowther MA, Ali MA, et al. The evaluation of various mathematical RBC indices and their efficacy in discriminating between thalassemic and non-thalassemic microcytosis. Am J Clin Pathol 1996;106:201-5.
107. Urrechaga E, Borque L, Escanero JF. Erythrocyte and reticulocyte parameters in iron deficiency and thalassemia. J Clin Lab Anal 2011;25:223-8.
108. Schoorl M, Schoorl M, Linssen J, et al. Efficacy of advanced discriminating algorithms for screening on iron-deficiency anemia and beta-thalassemia trait a multicenter evaluation. Am J Clin Pathol 2012;138:300-4.
109. d'Onofrio G, Zini G, Ricerca BM, et al. Automated measurement of red blood cell microcytosis and hypochromia in iron deficiency and b-thalassemia trait. Arch Pathol Lab Med 1992;116:84-9.
110. Liu TC, Seong PS, Lin TK. The erythrocyte cell hemoglobin distribution width segregates thalassemia traits from other nonthalassemic conditions with microcytosis. Am J Clin Pathol 1997;107:601-7.
111. Bunyaratvej A, Fucharoen S, Greenbaum A, et al. Hydration of red cells in alpha and beta thalassemias differs. A useful approach to distinguish between these red cell phenotypes. Am J Clin Pathol 1994;102:217-22.
112. Soranzo N, Spector TD, Mangino M, et al. A genome-wide metaanalysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet 2009;41: 1182-90.
113. Ganesh SK, Zakai NA, van Rooij FJ, et al. Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet 2009;41:1191-8.
114. Kamatani Y, Matsuda K, Okada Y, et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet 2010;42:210-15.
115. Li J, Glessner JT, Zhang H, et al. GWAS of blood cell traits identifies novel associated loci and epistatic interactions in Caucasian and African-American children. Hum Mol Genet 2013; 22:1457-64.
116. Mohandas N, Kim YR, Tycko DH, et al. Accurate and independent measurement of volume and hemoglobin concentration of individual red cells by laser light scattering. Blood 1986;68: 506-13.
117. Mohandas N, Johnson A, Wyatt J, et al. Automated quantitation of cell density distribution and hyperdense cell fraction in RBC disorders. Blood 1989;74:442-7.
118. Urrechaga E. The new mature red cell parameter, low haemoglobin density of the Beckman-Coulter LH750: clinical utility in the diagnosis of iron deficiency. Int J Lab Hematol 2010;32: e144-50.
119. Maconi M, Cavalca L, Danise P, et al. Erythrocyte and reticulocyte indices in iron deficiency in chronic kidney disease: comparison of two methods. Scand J Clin Lab Invest 2009;69: 365-70.
120. Urrechaga E, Borque L, Escanero JF. Biomarkers of hypochromia: the contemporary assessment of iron status and erythropoiesis. Biomed Res Int 2013;2013:603786.
121. Dopsaj V, Mikovic-Golubovic G, Martinovic J, et al. Evaluation of derived Coulter red blood cell parameters for the assessment of iron deficiency in adults with congenital heart disease. Int J Lab Hematol 2012;34:461-72.
122. Urrechaga E, Unceta M, Borque L, et al. Low hemoglobin density potential marker of iron availability. Int J Lab Hematol 2012;34: 47-51.
123. Schaefer RM, Schaefer L. The hypochromic red cell: a new parameter for monitoring of iron supplementation during rhEPO therapy. J Perinat Med 1995;23:83-8.
124. Braun J, Lindner K, Schreiber M, et al. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant 1997;12: 1173-81.
125. Bovy C, Tsobo C, Crapanzano L, et al. Factors determining the percentage of hypochromic red blood cells in hemodialysis patients. Kidney Int 1999;56:1113-19.
126. Schaefer RM, Schaefer L. Hypochromic red blood cells and reticulocytes. Kidney Int 1999;69:S44-8.
127. Tessitore N, Solero GP, Lippi G, et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 2001;16:1416-23.
128. Richardson D, Bartlett C, Will EJ. Optimizing erythropoietin therapy in hemodialysis patients. Am J Kidney Dis 2001;38: 109-17.
129. Rehu M, Ahonen S, Punnonen K. The diagnostic accuracy of the percentage of hypochromic red blood cells (%HYPOm) and cellular hemoglobin in reticulocytes (CHr) in differentiating iron deficiency anemia and anemia of chronic diseases. Clin Chim Acta 2011;412:1809-13.
130. Macdougall IC, Cavill I, Hulme B, et al. Detection of functional iron-deficiency during erythropoietin treatment - a new approach. Br Med J 1992;304:225-6.
131. Brugnara C, Chambers LA, Malynn E, et al. Red-blood-cell regeneration induced by subcutaneous recombinant erythropoietin - iron-deficient erythropoiesis in iron-replete subjects. Blood 1993;81:956-64.
132. Brugnara C, Colella GM, Cremins J, et al. Effects of subcutaneous recombinant-human-erythropoietin in normal subjects - development of decreased reticulocyte hemoglobin content and irondeficient erythropoiesis. J Lab Clin Med 1994;123:660-7.
133. Winkelmayer WC, Lorenz M, Kramar R, et al. Percentage of hypochromic red blood cells is an independent risk factor for mortality in kidney transplant recipients. Am J Transplant 2004;4: 2075-81.
134. Bhandari S, Norfolk D, Brownjohn A, et al. Evaluation of RBC ferritin and reticulocyte measurements in monitoring response to intravenous iron therapy. Am J Kidney Dis 1997;30:814-21.
135. Fishbane S, Galgano C, Langley Jr RC, et al. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 1997;52:217-22.
136. Verhovsek M, So CC, O'Shea T, et al. Is HbA2 level a reliable diagnostic measurement for beta-thalassemia trait in people with iron deficiency? Am J Hematol 2012;87:114-16.
137. Brugnara C, Laufer MR, Friedman AJ, et al. Reticulocyte hemoglobin content (CHr): early indicator of iron deficiency and response to therapy. Blood 1994;83:3100-1.
138. Mast AE, Blinder MA, Dietzen DJ. Reticulocyte hemoglobin content. Am J Hematol 2008;83:307-9.
139. Koury MJ. Abnormal erythropoiesis and the pathophysiology of chronic anemia. Blood Rev 2014;28:49-66.
140. Wilkinson N, Pantopoulos K. IRP1 regulates erythropoiesis and systemic iron homeostasis by controlling HIF2alpha mRNA translation. Blood 2013;122:1658-68.
141. Anderson SA, Nizzi CP, Chang YI, et al. The IRP1-HIF-2alpha axis coordinates iron and oxygen sensing with erythropoiesis and iron absorption. Cell Metab 2013;17:282-90.
142. Brugnara C. Use of reticulocyte cellular indices in the diagnosis and treatment of hematological disorders. Int J Clin Lab Res 1998; 28:1-11.
143. Brugnara C, Zelmanovic D, Sorette M, et al. Reticulocyte hemoglobin: an integrated parameter for evaluation of erythropoietic activity. Am J Clin Pathol 1997;108:133-42.
144. Torsvik IK, Markestad T, Ueland PM, et al. Evaluating iron status and the risk of anemia in young infants using erythrocyte parameters. Pediatr Res 2013;73:214-20.
145. Mast AE, Blinder MA, Lu Q, et al. Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. Blood 2002;99:1489-91.
146. Major A, Mathez-Loic F, Gautschi K, et al. The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. Br J Haematol 1997;98:292-4.
147. Ervasti M, Kotisaari S, Heinonen S, et al. Use of advanced red blood cell and reticulocyte indices improves the accuracy in diagnosing iron deficiency in pregnant women at term. Eur J Haematol 2007;79:539-45.
148. Cullen P, Soffker J, Hopfl M, et al. Hypochromic red cells and reticulocyte haemglobin content as markers of iron-deficient erythropoiesis in patients undergoing chronic haemodialysis. Nephrol Dial Transplant 1999;14:659-65.
149. Mittman N, Sreedhara R, Mushnick R, et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kid Dis 1997;30: 912-22.
150. Fishbane S, Shapiro W, Dutka P, et al. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 2001;60:2406-11.
151. Chuang CL, Liu RS, Wei YH, et al. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dialy Transplant 2003;18:370-7.
152. Kim JM, Ihm CH, Kim HJ. Evaluation of reticulocyte haemoglobin content as marker of iron deficiency and predictor of response to intravenous iron in haemodialysis patients. Int J Lab Hematol 2008;30:46-52.
153. Kaneko Y, Miyazaki S, Hirasawa Y, et al. Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients. Kidney Int 2003;63:1086-93.
154. Tsuchiya K, Okano H, Teramura M, et al. Content of reticulocyte hemoglobin is a reliable tool for determining iron deficiency in dialysis patients. Clin Nephrol 2003;59:115-23.
155. Chung M, Moorthy D, Hadar N, et al. Biomarkers for assessing and managing iron deficiency anemia in late-stage chronic kidney disease. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Oct. Report No.: 12(13)-EHC140-EF.
156. Brugnara C, Schiller B, Moran J. Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clin Lab Haematol 2006;28:303-8.
157. Ng HY, Chen HC, Pan LL, et al. Clinical interpretation of reticulocyte hemoglobin content, RET-Y, in chronic hemodialysis patients. Nephron Clin Pract 2009;111:C247-52.
158. Miwa N, Akiba T, Kimata N, et al. Usefulness of measuring reticulocyte hemoglobin equivalent in the management of haemodialysis patients with iron deficiency. Int J Lab Hematol 2010;32: 248-55.
159. Van Wyck DB, Alcorn Jr H, Gupta R. Analytical and biological variation in measures of anemia and iron status in patients treated with maintenance hemodialysis. Am J Kidney Dis 2010;56: 540-6.
160. Joosten E, Lioen P, Brusselmans C, et al. Is analysis of the reticulocyte haemoglobin equivalent a useful test for the diagnosis of iron deficiency anaemia in geriatric patients? Eur J Intern Med 2013;24:63-6.
161. Urrechaga E. Clinical utility of the new Beckman-Coulter parameter red blood cell size factor in the study of erithropoiesis. Int J Lab Hematol 2009;31:623-9.
162. Oustamanolakis P, Koutroubakis IE, Messaritakis I, et al. Measurement of reticulocyte and red blood cell indices in the evaluation of anemia in inflammatory bowel disease. J Crohn's Colitis 2011;5:295-300.
163. Skarmoutsou C, Papassotiriou I, Traeger-Synodinos J, et al. Erythroid bone marrow activity and red cell hemoglobinization in iron sufficient beta-thalassemia heterozygotes as reflected by soluble transferrin receptor and reticulocyte hemoglobin in content. Correlation with genotypes and Hb A(2) levels. Haematologica 2003;88:631-6.
164. Maier-Redelsperger M, Levy P, Lionnet F, et al. Strong association between a new marker of hemolysis and glomerulopathy in sickle cell anemia. Blood Cells Mol Dis 2010;45:289-92.
165. Novembrino C, Porcella A, Conte D, et al. Erythrocyte ferritin concentration: analytical performance of the immunoenzymatic IMx-Ferritin (Abbott) assay. Clin Chem Lab Med 2005;43: 449-53.
166. Galan P, Sangare N, Preziosi P, et al. Is basic red cell ferritin a more specific indicator than serum ferritin in the assessment of iron stores in the elderly? Clin Chim Acta 1990;189:156-62.
167. Labbe RF, Dewanji A, McLaughlin K. Observations on the zinc protoporphyrin/heme ratio in whole blood. Clin Chem 1999;45: 146-8.
168. Fishbane S, Lynn R. The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysispatients. Am J Kidney Dis 1995;25:426-32.
169. Braun J, Hammerschmidt M, Schreiber M, et al. Is zinc protoporphyria an indicator of iron-deficient erythropoiesis in maintenance haemodialysis patients? Nephrol Dial Transplant 1996;11:492-7.
170. Baldus M, Salopek S, Moller M, et al. Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialysis patients. Nephrol Dial Transplant 1996;11: 486-91.
171. Baldus M, Walter H, Thies K, et al. Transferrin receptor assay and zinc protoporphyrin as markers of iron-deficient erythropoiesis in end-stage renal disease patients. Clin Nephrol 1998;49: 186-92.
172. Hastka J, Lasserre JJ, Schwarzbeck A, et al. Washing erythrocytes to remove interferents in measurements of zinc protoporphyrin by front-face hematofluorometry. Clin Chem 1992;38:2184-9.
173. Garrett S, Worwood M. Zinc protoporphyrin and iron-deficient erythropoiesis. Acta Haematol 1994;91:21-5.
174. Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000;11:530-8.
175. Harrington AM, Kroft SH. Pencil cells and prekeratocytes in iron deficiency anemia. Am J Hematol 2008;83:927. doi: 10.1002/ajh.21283.
176. Harrington AM, Ward PCJ, Kroft SH. Iron deficiency anemia, beta-thalassemia minor, and anemia of chronic disease. Am J Clin Pathol 2008;129:466-71.
177. Fernandez-Rodriguez AM, Guindeo-Casasus MC, Molero-Labarta T, et al. Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis 1999;34:508-13.
178. Kalantarzadeh K, Hoffken B, Wunsch H, et al. Diagnosis of irondeficiency anemia in renal-failure patients during the posterythropoietin era. Am J Kidney Dis 1995;26:292-9.
179. Domrongkitchaiporn S, Jirakranont B, Atamasrikul K, et al. Indices of iron status in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1999;34:29-35.
180. Gotloib L, Silverberg D, Fudin R, et al. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 2006;19:161-7.
181. Barron BA, Hoyer JD, Tefferi A. A bone marrow report of absent stainable iron is not diagnostic of iron deficiency. Ann Hematol 2001;80:166-9.
182. Stancu S, Barsan L, Stanciu A, et al. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol 2010;5:409-16.
183. Iolascon A, De Falco L, Beaumont C. Molecular basis of inherited microcytic anemia due to defects in iron acquisition or heme synthesis. Haematologica 2009;94:395-408.
184. Byrne SL, Krishnamurthy D, Wessling-Resnick M. Pharmacology of iron transport. Annu Rev Pharmacol Toxicol 2013;53:17-36.
185. Camaschella C. How I manage patients with atypical microcytic anaemia. Br J Haematol 2013;160:12-24.
186. Donker AE, Raymakers RAP, Vlasveld LT, et al. Practice guidelines for the diagnosis and management of microcytic anemias due to genetic disorders of iron metabolism or heme synthesis. Blood 2014;123:3873-86.
187. Beutler E, Felitti V, Gelbart T, et al. Haematological effects of the C282Y HFE mutation in homozygous and heterozygous states among subjects of northern and southern European ancestry. Br J Haematol 2003;120:887-93.
188. Chambers JC, Zhang WH, Li Y, et al. Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet 2009;41:1170-2.
189. Torti L, Teofili L, Capodimonti S. Hypoxia-inducible factor-1aPro-582-Ser polymorphism prevents iron deprivation in healthy blood donors. Blood Transf 2013;4:553-7.
190. Gross SJ, Stuart MJ, Swender PT, et al. Malabsorption of iron in children with iron deficiency. J Pediatr 1976;88:795-9.
191. Conway RE, Geissler CA, Hider RC, et al. Serum iron curves can be used to estimate dietary iron bioavailability in humans. J Nutr 2006;136:1910-14.
192. Rutherford CJ, Schneider TJ, Dempsey H, et al. Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated perisurgical setting: the importance of iron availability in optimizing response. Am J Med 1994;96:139-45.
193. Thomas DW, Hinchliffe RF, Briggs C, et al. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol 2013;161:639-48.
194. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004;116 Suppl 7A:11S-26S.
195. Macciò A, Madeddu C, Gramignano G, et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica 2014;100:124-32.
196. Gilreath JA, Stenehjem DD, Rodgers GM. Diagnosis and treatment of cancer-related anemia. Am J Hematol 2014;89:203-12.
197. Annen K, Delaney M, Leitch D, et al. The health implications of low hemoglobin deferral in infrequent blood donors. Transfusion 2015;55:86-90.
198. Cable RG, Glynn SA, Kiss JE, et al. Iron deficiency in blood donors: the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion 2012;52:702-11.
199. O'Meara A, Infanti L, Stebler C, et al. The value of routine ferritin measurement in blood donors. Transfusion 2011;51:2183-8.
200. Kiss JE, Steele WR, Wright DJ, et al. Laboratory variables for assessing iron deficiency in REDS-II Iron Status Evaluation (RISE) blood donors. Transfusion 2013;53:2766-75.
201. Hoppe M, Hulthen L, Hallberg L. The validation of using serum iron increase to measure iron absorption in human subjects. Br J Nutr 2004;92:485-8.
202. Lin XM, Tian W, Ma L, et al. The responses of serum transferrin receptors to iron supplements in subjects with iron-deficiency erythropoiesis and iron-deficiency anaemia. Br J Nutr 2008;99: 416-20.
203. Major A, MathezLoic F, Rohling R, et al. The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. Br J Haemat 1997;98:292-4.
204. Branten AJW, Swinkels DW, Klasen IS, et al. Serum ferritin levels are increased in patients with glomerular diseases and proteinuria. Nephrol Dialy Transplant 2004;19:2754-60.
205. Vagace JM, Rodriguez MA, de la Maya MD, et al. Ethylenediaminetetraacetic acid-dependent pseudomacrocytosis. J Clin Pathol 2013;66:811-14.
206. Ermens AAM, Hoffmann J, Krockenberger M, et al. New erythrocyte and reticulocyte parameters on CELL-DYN Sapphire: analytical and preanalytical aspects. Int J Lab Hematol 2012;34:274-82.
207. Hoffmann J, van den Broek NMA, Curvers J. Reference intervals of extended erythrocyte and reticulocyte parameters. Clin Chem Lab Med 2012;50:941-8.
208. Dopsaj V, Martinovic J, Dopsaj M. Early detection of iron deficiency in elite athletes: could microcytic anemia factor (Maf) be useful? Int J Lab Hematol 2014;36:37-44.